Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000724793 | SCV000227989 | uncertain significance | not provided | 2015-05-05 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000724793 | SCV000582235 | uncertain significance | not provided | 2017-04-13 | criteria provided, single submitter | clinical testing | The R15986H variant is observed in 8/66696 (0.01%) alleles from individuals of European background (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). This substitution occurs at a position that is conserved in mammals, and in silico analysis predicts this variant is probably damaging to the protein structure/function. However, this variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Additionally, the majority of disease associated pathogenic variants in the TTN gene are loss of function and result from truncating variants. |
Labcorp Genetics |
RCV000539172 | SCV000643329 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2018-01-05 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002478576 | SCV002788410 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J; Tibial muscular dystrophy; Myopathy, myofibrillar, 9, with early respiratory failure; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2021-10-20 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000724793 | SCV003825592 | uncertain significance | not provided | 2022-06-07 | criteria provided, single submitter | clinical testing |